Member Info for nursesteve

April should be news rich. Data at the conference and as per RNS Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April. All within a new isa and sipp allowance period.

Maybe Alan decimated the Share Price (and overall value of the company) just so big Pharma can swoop in?

They don’t do boosts but they certainly torpedoed the SP with this raise. 50% drop in SP for about a 20/25% increase in the number of shares = a major torpedo! 🚀 not the rocket I was hoping for 😒

Appreciate the replies guys. I guess we all agree the current price is cheap?

It’s not odd it dropped but by this much is of note

Sage my point being the overall value of the company has dropped yet we are now funded and have several value inflection points, including the desire and ability to progress our lead asset AVA6000

So the company now has 350,512,279 shares after issuing 62,296,557 as part of the recent cash raise about 20-25% increase in shares. Yet the price fell about 50% from its aprox value before the rumours ?

I think it might well go a lot higher!

Nice that I called the bounce at 72p be even nicer if I had gone all in then! GLA

Good luck to you Sitiaian. We all have to do what we’re comfortable doing. I’m holding on tight till real news. GLA

Watch it bounce up from here!

My answer to sage was quoting back what they had said on 26 Jan

You are generally right hunky monkey. Fortunately I’m not reliant on my isa and sipp and my wife’s pension and sipp aren’t at risk. I already have a service pension and war pension and the house is paid off so my money my risk! Hence not advice for anyone else to follow!

Sage

I think it’s a great opportunity and believe in it wholeheartedly medium - long term.

I’ve gone all in with my isa and Sipp. Happy to take the risk. GLA

DTW thanks. I’ve also added a few more to my holding today and happy to wait now. GL

Just to add - they also stated in another answer that the Phase 2 study was expected to begin in 2H24 so 🤞IMHO ‘pivotal’ SP news will be released before that. GLA

That’s a lot of money RMFatGB!

Just been reading through some of the Q&A on the presentation of 13th Dec. & this answer stood out

Please note: We cannot provide specific details of ongoing business development discussions not only because this is inappropriate from a market sensitive information perspective but also because it would actually jeopardise these potential relationships. The high level commercial strategy was set out at the AGM in June 2023; this strategy has not changed. (For reference, slide 11 here: https://avacta.com/wp-content/uploads/2023/06/Avacta-AGM-2023-presentations.pdf). The Company has the opportunity to commercialise both its specific assets, such as AVA6000 or AVA3996, and its platform technologies - pre|CISION and Affimer. It is strategically important for the company to continue to wholly own its lead clinical programme – AVA6000 – for now. Taking this asset into phase 2 not only adds value for shareholders by generating efficacy data but also maintains Avacta’s clinical stage status which is important for attracting specialist healthcare investors. Avacta therefore plans to take AVA6000 into phase 2 and will then consider partnering this asset to take it to market and to broaden its applications into other cancer indications. There is potential to partner AVA3996 or any other undisclosed pipeline assets at a preclinical stage. More importantly in the short term is the potential to partner the pre|CISION platform. This means potentially licensing the platform to a third party to use in combination with their own cytotoxic agent. Such a licensing deal would be expected to be narrowly focused on a specific agent or agents. The clinical data published on December 13th 2023 plays a pivotal role in generating business development discussions and accelerating those that are ongoing.

So the appointment of Dr Simon ‘to accelerate ongoing discussions’ on 19th Dec should hopefully result in news of a partnership deal as mentioned ‘in the short term’ - before phase 2 of AVA6000

Toatie I’m fairly sure they mentioned it in answer to shareholders questions on the investor meet website https://www.investormeetcompany.com/avacta-group-plc

Nice that the employees are getting rewarded.

I’d be surprised if we weren’t in negotiation with other company’s after the Appointment by Avacta of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division. Which they said ‘signals commercial emphasis for Avacta to leverage clinical progress’. No doubt he is ‘just getting on with it’ but let’s hope we hear news soon! GLA

“The efficacy and side effects are therefore significantly improved." 🤔 could well be us?